Intuitive Surgical (ISRG) currently has the kind of dominance that makes investors giddy and skeptics nervous.

The company owns 95%+ of the robotic-assisted surgery market, posted 23% revenue growth in Q3 2025 on 19% procedure volume gains, and just placed 427 da Vinci systems in a single quarter.

I’m holding my position, my second-largest healthcare holding after UnitedHealth, and I've owned this stock through every major drawdown since 2019.

Here is what has my attention at the moment:

On December 3rd, 2025, Medtronic got FDA clearance for its Hugo robotic surgery system in urology, the first credible competitive threat Intuitive has faced in 25 years. Hugo is modular, potentially cheaper, and Medtronic can bundle it with other surgical products to win hospital contracts.

Meanwhile, ISRG trades at 72x trailing earnings and 58x forward earnings, nearly double its 10-year average P/E of 40x. Q4 2025 earnings drop on January 22nd, and if procedure growth decelerates or Medtronic announces aggressive Hugo pricing, this stock could give back ground fast.

The bull case is straightforward. Recurring revenue from instruments and service contracts makes this a high-quality compounder.

Every da Vinci procedure generates $1,500-2,000 in instrument revenue with 75%+ gross margins, and Intuitive's installed base grew 13% to 10,763 systems in Q3. As long as hospitals keep doing surgeries, and surgeons who trained on da Vinci don't want to learn a new system, this business prints money.

The bear case? We're about to find out if this valuation at 72x P/E can survive actual competition.

Intuitive Surgical pioneered robotic-assisted surgery with the da Vinci system - a massive multi-armed robot that lets surgeons perform minimally invasive procedures through tiny incisions while sitting at a console.

The company makes money three ways:

The business model is brilliant. Once a hospital buys a da Vinci system and trains its surgeons, switching costs are enormous. You've invested millions in the capital equipment, spent months training surgical teams, and your surgeons are now proficient on this specific platform. Switching to Medtronic's Hugo means retraining everyone, reoptimizing workflows, and explaining to patients why you're using a less-proven system. That's a fortress-level moat.

As of Q3 2025, Intuitive had 10,763 da Vinci systems installed worldwide - up 13% year-over-year.

In my opinion the most impressive result from the last earnings report is procedure volume growth.

In Q3, da Vinci procedures grew 19% to approximately 680,000 procedures in Q3 alone. That translates to recurring instrument and accessory revenue of $1.52 billion in the quarter, up 20% from prior year. Service revenue hit $396 million, also up 20%. This is 75%+ of total revenue coming from the installed base, not new system sales. That's the quality you're paying for at this valuation.

The da Vinci 5 - which launched broadly in early 2025 - is the most significant upgrade in a decade. It features improved imaging, enhanced wristed instruments, AI-powered surgical guidance, and integration with Intuitive's digital Hub for real-time data analytics.

In Q3 2025, Intuitive placed 240 da Vinci 5 systems out of 427 total placements. Hospitals are paying $2-2.5 million per da Vinci 5 compared to $1.5 million for older models, and da Vinci 5 drives higher per-procedure instrument revenue because it enables more complex surgeries. This is margin accretive to the business over time.

The installed base flywheel is accelerating, not decelerating.

Procedure growth of 19% in Q3 2025 marks an acceleration from 17% growth in 2024 and 14% in 2023.

Think about what this means. Intuitive isn't growing because it's placing dramatically more systems - 13% installed base growth is consistent with recent years. It's growing because utilization per system is increasing.

Hospitals that bought da Vinci 5 systems are doing 4% more procedures per system than those with older models, and surgeons are expanding into new procedure types - colorectal, thoracic, gynecology - that weren't common five years ago.

The whitespace opportunity is massive. In the U.S., less than 10% of eligible surgeries are performed robotically. See the NIH report here.

As surgeon training expands and clinical evidence builds, these lower-penetration specialties are the next decade of growth. Intuitive doesn't need to invent new markets - it just needs to convert traditional laparoscopic surgeries to robotic, which is already happening organically.

Da Vinci 5's clinical advantages create genuine differentiation.

I've spoken to three urologists and two general surgeons who've used both da Vinci 5 and older da Vinci systems. They universally cite Force Feedback (haptic sensation when instruments touch tissue), improved 3D visualization, and the digital Hub's intraoperative guidance as game-changers for complex cases.

This is clinically meaningful innovation that makes surgeons prefer da Vinci 5 over alternatives, including Medtronic's Hugo.

The recurring revenue model compounds at 20%+ annually with expanding margins.

In Q3 2025, instrument and accessory revenue grew 20%, service revenue grew 20%, and total recurring revenue (which includes leased systems) represented 75% of total revenue.

Non-GAAP gross margins were 68.8% in Q3, compressed from 69.7% a year ago due to tariffs and higher da Vinci 5 manufacturing costs, but management guided to 67-67.5% for full-year 2025. Once da Vinci 5 production scales and tariff headwinds ease, I expect margins to trend back toward 70%.

The beautiful part? These margins improve as the installed base grows. A hospital with one da Vinci system doing 200 procedures annually generates $300,000 in instrument revenue.

That same hospital with two systems doing 400 procedures generates $600,000, but Intuitive's service cost doesn't double. The incremental margin on additional procedures from existing customers is 80-85%. This is real operating leverage.

International expansion is in the second inning.

The U.S. represents 65% of Intuitive's revenue, but international markets, particularly Europe and Asia, are growing faster.

In Q3, international procedures grew 22% versus 17% in the U.S. Japan just approved da Vinci 5 in October 2025, and China is expanding (despite economic headwinds).

International markets have 30-40% lower procedure penetration than the U.S., and as healthcare systems in Europe, Japan, and eventually China invest in robotic surgery, Intuitive has a head start to capture market share before competitors establish presence, but will of course have to execute to justify their growth projections in these markets.

Medtronic's Hugo just became real competition, not theoretical.

On December 3rd, 2025, the FDA cleared Medtronic's Hugo robotic system for urological procedures. This is the first time Intuitive faces a competitor with deep pockets, global distribution, and the ability to bundle robotic systems with other surgical products (staplers, energy devices, imaging) to win hospital contracts. Medtronic can offer hospitals a $500K discount on Hugo if they also buy Medtronic's full surgical portfolio.

That's a total package that Intuitive can't match because it only sells robotic systems.

Hugo completed clinical trials showing 100% surgical success rates in hernia repair, and Medtronic expects FDA clearances for general surgery and gynecology by mid-2026.

If Hugo captures even 10-15% market share in new system placements over the next three years, that's 500-700 systems Intuitive doesn't sell. More concerning, if Hugo proves clinically equivalent at a lower total cost of ownership, hospitals with aging da Vinci Xi systems might choose Hugo for replacement, breaking Intuitive's upgrade cycle.

Valuation leaves zero room for error.

At $586 with a $208 billion market cap, ISRG trades at 72x trailing earnings and 63x forward earnings based on 2026 EPS estimates of $10.

The 10-year historical P/E for this stock is 40x. Even at the peak of the COVID recovery in 2021, ISRG only traded at 65x forward earnings. Today's 72x assumes procedure growth sustains at 17-20% annually, margins expand back to 70%, and Hugo doesn't meaningfully impact market share.

If any of those assumptions break, the stock reprices violently.

If procedure growth decelerates to 10-12% and the market assigns a 45x forward P/E (still premium but more normalized), you're looking at a fair value of $400-450.

That's 30% downside from current levels. For a stock trading at this valuation, 20-25% of the return needs to come from multiple expansion, not just earnings growth. That makes me nervous because we're already near peak valuations.

Tariffs are compressing margins by 70 basis points, and the impact could worsen.

In Q3 guidance, Intuitive disclosed that current tariffs on components manufactured in China and imported to the U.S. are costing 70 basis points of gross margin (approximately $17 million quarterly). Management warned that if additional tariffs are implemented in 2026 - which is possible given current trade tensions - the impact could be "material."

If tariffs increase another 10 percentage points on Chinese components, that's another 100-150 basis points of margin pressure. At 68% gross margins, that would drop Intuitive to 66-67%, which is a clear headwind to earnings growth.

Bariatric surgery volumes are declining, and that's a $200M+ revenue headwind.

Intuitive generates significant revenue from robotic bariatric surgery (gastric bypass, sleeve gastrectomy), but volumes have been declining as GLP-1 drugs like Ozempic and Wegovy reduce obesity surgery demand. Management noted on the Q3 call that U.S. bariatric procedures continue to decline year-over-year.

If GLP-1 adoption accelerates - and it will - bariatric surgery could drop 20-30% over three years. That's $50-70 million in annual instrument revenue at risk, which is manageable but not nothing for a company this size.

ISRG trades at 72x trailing earnings, 63x forward earnings, and 22x trailing sales. Analysts have an average price target of $595-611, implying just 1.5-4% upside over the next 12 months. That's not compelling for a stock with this much volatility.

The bull case gets you to $700-750 if procedure growth sustains, da Vinci 5 drives margin expansion back up to 70%+, and Hugo turns out to be a non-factor. That's 20-28% upside over 24 months, which is solid but requires everything going right.

The bear case - where Hugo captures 15% market share in new placements, procedure growth decelerates, and tariffs compress margins further - puts fair value at $450-500. That's 20-25% downside.

I'm holding my position because I believe Intuitive's recurring revenue model, switching costs, and clinical advantages justify a premium valuation. But I'm not adding at current prices. For this to be a buy, I'd want to see either:

(1) a 15-20% pullback to $480-500

Or

(2) Q4 earnings showing procedure growth reaccelerating to 20%+ and management dismissing Hugo as competitively irrelevant.

For aggressive growth portfolios with 10+ year time horizons, ISRG can be a position. You're betting that robotic surgery penetration grows from 10% to 40%+ over the next decade, and Intuitive maintains dominant market share through switching costs and continuous innovation.

For moderate portfolios or anyone uncomfortable with 30-40% drawdowns if the growth narrative stumbles, this should be only a small position or disregarded.

Q4 2025 earnings on January 22nd, 2026 will be the most important catalyst in months.

(1) Full-year procedure growth - did it hit the 17-17.5% guidance range or surprise higher?

(2) Da Vinci 5 placements - did momentum continue with 200+ units in Q4?

(3) International growth - is Europe/Asia offsetting any U.S. softness?

(4) Any commentary on Hugo competition - is management concerned, dismissive, or somewhere in between?

Medtronic's Hugo rollout in the U.S. through Q1-Q2 2026. Track how many Hugo systems Medtronic places in the first two quarters post-FDA clearance. If they place 50-100 systems by June 2026, that's a credible competitive threat. If they only place 10-20, it signals the market isn't interested in switching. Also watch for hospital case studies—if major academic medical centers announce Hugo purchases, that's a red flag for Intuitive's moat.

Gross margin trajectory through 2026. Management guided to 67-67.5% for 2025 due to tariffs and da Vinci 5 ramp costs. If margins stay compressed at 67% through mid-2026, the market will punish the stock because it signals structural margin pressure, not temporary headwinds. I want to see margins trend back toward 69-70% by Q3 2026 as da Vinci 5 scales.

New clinical approvals and procedure category expansion. On December 10th, 2025, Intuitive announced expanded indications for da Vinci SP (single-port system) in colorectal and thoracic surgery. These are lower-penetration categories with huge growth potential. Watch for adoption metrics in Q1-Q2 2026—if SP procedure volumes grow 30-40%, that's a new growth driver that offsets any Hugo competition.

Intuitive Surgical is still the best-in-class robotic surgery company with a business model that compounds cash flow at 20% annually. But at this valuation you're paying for perfection. With Medtronic's Hugo finally in the U.S. market, tariffs compressing margins, and bariatric volumes declining, this stock needs to execute flawlessly to justify current valuation.

I'm holding my position because I believe in the long-term thesis, but I'm not adding until we see how Hugo competition plays out and valuation compresses to 50-55x forward earnings.

For new buyers, I’d recommend you wait for Q4 earnings on January 22nd and look for a pullback toward $500 to establish new positions.

The Earnout Investor provides analysis and research but DOES NOT provide individual financial advice. Jamie Dejter may have a position in some of the stocks mentioned. All content is for informational purposes only. The Earnout Investor is not a registered investment, legal, or tax advisor, or a broker/dealer. Trading any asset involves risk and could result in significant capital losses. Please, do your own research before acquiring stocks.